Granted Patent
B2
US 12,529,073 · App. 16/338,295 · Granted Jan 20, 2026
Viral vectors for nuclear reprogramming
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This document provides materials and methods involved in making and using induced pluripotent stem cells (iPSCs). For example, measles virus vectors for reprogramming somatic cells into iPSCs, methods for obtaining iPSCs, and methods for using iPSCs are provided.
Claims (13)
1 . A Paramyxoviridae viral vector for reprogramming somatic cells into iPSCs, wherein said vector comprises negative-strand RNA comprising a first sequence that produces a mRNA molecule encoding a first reprogramming factor, a second sequence that produces a mRNA molecule encoding a second reprogramming factor, a third sequence that produces a mRNA molecule encoding a Paramyxoviridae virus N polypeptide, a fourth sequence that produces a mRNA molecule encoding a Paramyxoviridae virus P polypeptide, a fifth sequence that produces a mRNA molecule encoding a Paramyxoviridae virus M polypeptide, a sixth sequence that produces a mRNA molecule encoding a Paramyxoviridae virus F polypeptide, and a seventh sequence that produces a mRNA molecule encoding a Paramyxoviridae virus L polypeptide, wherein one or more of said mRNA molecules comprises a nucleic acid sequence complementary to a microRNA (miRNA) associated with pluripotency located within a 3′ untranslated region of said one or more mRNA molecules, wherein said miRNA is miR375, wherein said first and second sequences are located between said sixth and seventh sequences, wherein said miRNA is endogenous to said iPSCs and in an amount sufficient to (a) reduce a level of said vector within said iPSCs or (b) reduce expression of one or more of said first and said second reprogramming factors in said iPSCs.
2 . The vector of claim 1 , wherein said first reprogramming factor comprises OCT4.
3 . The vector of claim 1 , wherein said nucleic acid sequence complementary to said miRNA is located in a 3′ untranslated region of said mRNA molecule encoding said Paramyxoviridae virus P polypeptide.
4 . The vector of claim 1 , wherein said first reprogramming factor comprise OCT4, and wherein said nucleic acid sequence complementary to said miRNA is located in a 3′ untranslated region of said mRNA molecule encoding said Paramyxoviridae virus P polypeptide.
5 . The vector of claim 1 , wherein said 3′ UTR of said mRNA molecule encoding said Paramyxoviridae virus P polypeptide comprises more than one copy of said nucleic acid sequence complementary to said miRNA.
6 . The vector of claim 1 , wherein said nucleic acid sequence complementary to miR375 comprises SEQ ID NO:1.
7 . The vector of claim 1 , wherein said first reprogramming factor comprises SOX2.
8 . The vector of claim 1 , wherein said first reprogramming factor comprises KLF4.
9 . The vector of claim 2 , wherein said second reprogramming factor comprises SOX2.
10 . The vector of claim 2 , wherein said second reprogramming factor comprises KLF4.
11 . The vector of claim 9 , wherein said negative-strand RNA comprises an eighth sequence that produces a mRNA encoding a third reprogramming factor.
12 . The vector of claim 11 , wherein said third reprogramming factor comprises KLF4.
13 . The vector of claim 12 , wherein said negative-strand RNA comprises a ninth sequence that produces a mRNA encoding a fourth reprogramming factor, wherein said fourth reprogramming factor comprises cMYC.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 15, 2020
From: DEVAUX, PATRICIA; IKEDA, YASUHIRO
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 052408/0446 →
Continuity (2)
Provisional Application
62402310
· Sep 30, 2016
References Cited (261)
US 8048999B2
· Yamanaka et al.
· 2011
[cited by applicant]
US 8058065B2
· Yamanaka et al.
· 2011
[cited by applicant]
US 8129187B2
· Yamanaka et al.
· 2012
[cited by applicant]
US 8173118B2
· Terzic
· 2012
[cited by applicant]
US 8278104B2
· Yamanaka et al.
· 2012
[cited by applicant]
US 9127256B2
· Fusaki et al.
· 2015
[cited by applicant]
US 9932561B2
· Thatava
· 2018
[cited by applicant]
US 20040241838A1
· Johnson et al.
· 2004
[cited by applicant]
US 20120164731A1
· Sakurai et al.
· 2012
[cited by applicant]
US 20130029416A1
· Thatava et al.
· 2013
[cited by applicant]
US 20170009210A1
· Ikeda et al.
· 2017
[cited by applicant]
US 20180187161A1
· Thatava et al.
· 2018
[cited by applicant]
US 20180320143A1
· Ikeda et al.
· 2018
[cited by applicant]
EP 1970446
· 2008
[cited by applicant]
EP 2669381
· 2013
[cited by applicant]
EP 3216868
· 2017
[cited by applicant]
WO WO2007054720
· 2007
[cited by applicant]
WO WO2007069666
· 2007
[cited by applicant]
WO WO2008066630
· 2008
[cited by applicant]
WO WO2008088882
· 2008
[cited by applicant]
WO WO2009032194
· 2009
[cited by applicant]
WO 2010003420
· 2010
[cited by examiner]
WO WO2010017652
· 2010
[cited by applicant]
WO WO2013104728
· 2013
[cited by applicant]
WO WO2014037574
· 2014
[cited by applicant]
WO WO2015119995
· 2015
[cited by applicant]
WO WO2016034095
· 2016
[cited by applicant]
WO WO2016120493
· 2016
[cited by applicant]
Anokye-Danso et al. “How microRNAs facilitate reprogramming to pluripotency.” Journal of cell science 125.18 (2012): 4179-4787 (Year: 2012).
[cited by examiner]
Driscoll et al. “Nuclear reprogramming with a non-integrating human RNA virus.” Stem Cell Research & Therapy 6 (2015): 1-13 (Year: 2015).
[cited by examiner]
Abe et al., “Ex vivo expansion of human HSCs with Sendai virus vector expressing HoxB4 assessed by sheep in utero transplantation,” Experimental hematology, 39(1):47-54, Jan. 2011.
[cited by applicant]
Apolonia et al., “Stable gene transfer to muscle using non-integrating lentiviral vectors,” Mol. Ther., 15(11): 1947-1954, Nov. 2007.
[cited by applicant]
Audsley and Moseley, “Paramyxovirus evasion of innate immunity: Diverse strategies for common targets,” World J. Virol., 2(2):57-70, May 2013.
[cited by applicant]
Ban et al., “Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors,” Proc. Natl. Acad. Sci. USA., 108(34):14234-9, Aug. 2011.
[cited by applicant]
Banasik et al., “Integrase-defective lentiviral vectors: progress and applications,” Gene Ther., 17(2):150-157, Epub Oct. 22, 2009.
[cited by applicant]
Behfar et al., “Cardiopoietic programming of embryonic stem cells for tumor-free heart repair,” J. Exp. Med., 204(2):405-420, Feb. 2007.
[cited by applicant]
Behfar et al., “Stem cell differentiation requires a paracrine pathway in the heart,” FASEB J., 16(12):1558-1566, Oct. 2002.
[cited by applicant]
Bilic and Belmonte, “Concise Review: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells: Close Enough or Yet Too Far Apart?” Stem Cell Res., 33:33-41, 2012.
[cited by applicant]
Bitzer et al., “Sendai virus vectors as an emerging negative-strand RNA viral vector system,” J. Gene. Med., 5(7):543-53, Jul. 2003.
[cited by applicant]
Borowiak et al., “Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells,” Cell Stem Cell, 4(4):348-358, Apr. 2009.
[cited by applicant]
Brunel et al., “Sequence of events in measles virus replication: role of phosphoprotein-nucleocapsid interactions,” Journal of Virology, 88(18):10851-63, Sep. 2014.
[cited by applicant]
Buteau et al., “Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor,” Diabetes, 52:124-132, Jan. 2003.
[cited by applicant]
Carey et al., “Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells,” Cell Stem Cell, 9(6):588-598, Dec. 2011.
[cited by applicant]
Chen et al., “A small molecule that directs differentiation of human ESCs into the pancreatic lineage,” Nat Chem Biol., 5(4):258-265, Epub Mar. 15, 2009 with 20 pages Supplementary Material.
[cited by applicant]
Chung et al., “Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells,” Nat. Clin. Pract. Cardiovasc. Med., 4 Suppl 1, S60-67 Feb. 2007.
[cited by applicant]
Daheron et al., “LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells,” Stem Cells, 22(5):770-778, 2004.
[cited by applicant]
D'Amour et al., “Efficient differentiation of human embryonic stem cells to definitive endoderm,” Nat. Biotechnol., 23(12):1534-1541, Dec. 2005.
[cited by applicant]
del Valle et al., “A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge,” J. Virol., 81(19):10597-605, Oct. 2007.
[cited by applicant]
Demaison et al., “High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an interna…
[cited by applicant]
Devaux and Cattaneo, “Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function,” J. Virol., 78(21):11632-40, Nov. 2004.
[cited by applicant]
Devaux et al., “A recombinant measles virus unable to antagonize STATI function cannot control inflammation and is attenuated in rhesus monkeys,” J. Virol., 85(1):348-56, Jan. 2011.
[cited by applicant]
Devaux et al., “Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys,” Journal of Virology, 82(11):5359-67, Jun. 2008.
[cited by applicant]
Devaux et al., “The measles virus phosphoprotein interacts with the linker domain of STATI,” Virology, 444(1-2):250-6, Sep. 2013.
[cited by applicant]
Devaux et al., “Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation,” Virology, 360(1):72-83, Mar. 2007.
[cited by applicant]
Dietz et al., “A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers,” Transfusion, 46(12):2083-9, Dec. 2006.
[cited by applicant]
Driscoll et al., “Nuclear reprogramming with a non-integrating human RNA virus,” Stem Cell Research and Therapy, 6(1):48, Dec. 2015.
[cited by applicant]
Evans and Kaufman, “Establishment in culture of pluripotential cells from mouse embryos,” Nature, 292(5819):154-156, Jul. 1981.
[cited by applicant]
Extended European Search Report in European Application No. 17857486.9, dated Jul. 5, 2019, 4 pages.
[cited by applicant]
Faustino et al., “Genomic chart guiding embryonic stem cell cardiopoiesis ,” Genome Biol., 9(1):R6, Jan. 2008.
[cited by applicant]
Felgner et al., “Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations,” J. Biol. Chem., 269(4):2550-2561, Jan. 1994.
[cited by applicant]
Feng et al., “Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells,” Cell Stem Cell, 4(4):301-312, Apr. 2009.
[cited by applicant]
Finkel and Holbrook, “Oxidants, oxidative stress and the biology of ageing,” Nature, 408(6809):239-247, Nov. 2000.
[cited by applicant]
Flotte et al., “Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector,” Proc. Natl. Acad. Sci. USA, 90(22):10613-10617, Nov. 1993.
[cited by applicant]
Fujii and Martin, “Incorporation of teratocarcinoma stem cells into blastocysts by aggregation with cleavage-stage embryos,” Dev. Biol., 74(1): 239-244, Jan. 1980.
[cited by applicant]
Fusaki et al., “Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome,” Proc. Jpn. Acad. Ser. B. Phys. Biol. S…
[cited by applicant]
Galanis et al., “Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer,” Cancer Res., 70(3):875-82, Feb. 2010.
[cited by applicant]
GenBank Accession No. EU332921.1, “Measles virus strain Rouvax-schwarz phosphoprotein (P), V protein (P), and C protein (P) genes, complete cds” dated Dec. 31, 2008, 2 pages.
[cited by applicant]
GenBank® GI No. 109659099, Accession No. BC117435, “
[cited by applicant]
GenBank® GI No. 12652778, Accession No. BC000141, “
[cited by applicant]
GenBank® GI No. 163659904, Accession No. NM_000618, “
[cited by applicant]
GenBank® GI No. 188595715, Accession No. NM_001127500, “
[cited by applicant]
GenBank® GI No. 20987475, Accession No. BC029923, “
[cited by applicant]
GenBank® GI No. 255090638, Accession No. GQ351295, “
[cited by applicant]
GenBank® GI No. 291190799, Accession No. NM_002054.3, “
[cited by applicant]
GenBank® GI No. 33869633, Accession No. BC013923, “
[cited by applicant]
GenBank® GI No. 33872076, Accession No. BC028566, “
[cited by applicant]
GenBank® GI No. 71043476, Accession No. BC099704.1, “
[cited by applicant]
Gerlier and Valentin, “Measles virus interaction with host cells and impact on innate immunity,” Curr. Top Microbiol. Immunol., 329:163-91, 2009.
[cited by applicant]
Gerlier et al., “Subversion of the immune system by measles virus: a model for the intricate interplay between a virus and the human immune system,” Microbial Subversion of Immunity: Current Topics, 2006:225-92, 2006.
[cited by applicant]
Golipour et al., “A late transition in somatic cell reprogramming requires regulators distinct from the pluripotency network,” Cell Stem Cell., 11(6):769-82, Dec. 2012.
[cited by applicant]
Hanna et al., “Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin,” Science., 318:1920-1923, Dec. 21, 2007.
[cited by applicant]
Hasegawa et al., “Affinity thresholds for membrane fusion triggering by viral glycoproteins,” J. Virol., 81(23):13149-57, Dec. 2007.
[cited by applicant]
Hasegawa et al., “The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer,” Clin. Cancer Res., 12(20 Pt1):6170-6178, Oct. 2006.
[cited by applicant]
Hinton et al., “A distinct microRNA signature for definitive endoderm derived from human embryonic stem cells,” Stem Cells Dev., 19(6):797-807, Jun. 2010.
[cited by applicant]
Hiramoto et al., “Newly developed measles viral vector can efficiently transduce multiple genes into naïve T cells,” Blood, 124(21):4798, Dec. 2014.
[cited by applicant]
Hodgson et al., “Stable benefit of embryonic stem cell therapy in myocardial infarction,” Am. J. Physiol. Heart Circ. Physiol., 287(2):H471-479, Aug. 2004.
[cited by applicant]
Huangfu et al., “Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2,” Nat Biotechnol., 26(11): 1269-1275, Nov. 2008.
[cited by applicant]
Ikeda et al., “Continuous high-titer HIV-1 vector production,” Nat. Biotechnol., 21(5):569-572, May 2003.
[cited by applicant]
Ikeda et al., “Gene transduction efficiency in cells of different species by HIV and EIAV vectors,” Gene Ther., 9(14):932-938, Jul. 2002.
[cited by applicant]
Ikeda et al., “Influence of gag on human immunodeficiency virus type 1 species-specific tropism,” J. Virol., 78(21):11816-11822, Nov. 2004.
[cited by applicant]
International Search Report & Written Opinion in International Application No. PCT/US2017/054268 dated Feb. 23, 2018, 15 pages.
[cited by applicant]
Jaenisch and Young, “Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming,” Cell, 132(4): 567-582, Feb. 2008.
[cited by applicant]
Jia et al., “A nonviral minicircle vector for deriving human iPS cells,” Nature Methods, 7(3):197-9, Mar. 2010.
[cited by applicant]
Jiang et al., “Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells,” Nat Commun., 3:668, 9 pages, Feb. 2012.
[cited by applicant]
Kaji et al., “Virus-free induction of pluripotency and subsequent excision of reprogramming factors,” Nature, 458(7239):771-775, Apr. 2009.
[cited by applicant]
Kaplitt et al., “Long-term gene expression and phenotypic correction using adeno- associated virus vectors in the mammalian brain,” Nat. Genet., 8(2):148-154, Oct. 1994.
[cited by applicant]
Karakikes et al., “Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes,” Stem Cells Transl Med., 3(1):18-31, Jan. 2014.
[cited by applicant]
Kay et al., “Gene therapy,” Proc. Natl. Acad. Sci. USA, 94(24):12744-12746, Nov. 1997.
[cited by applicant]
Kim et al., “Epigenetic memory in induced pluripotent stem cells,” Nature., 467(7313):285-290, Sep. 2010.
[cited by applicant]
Kootstra et al., “Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells,” Proc. Natl. Acad. Sci. USA, 100(3):1298-1303, Feb. 2003.
[cited by applicant]
Kroon et al., “Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo,” Nat Biotechnol., 26(4):443-452, Epub Feb. 20, 2008.
[cited by applicant]
Kudva et al., “Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes,” Stem Cell Transl. Med., 1(6):451-61, Jun. 2012.
[cited by applicant]
Lamb and Kolakofsky, “Paramyxoviridae: The viruses and their replication,” B. N. Fields DMK, and P. M. Howley, editor. Fields Virology., 5th ed. Philadelphia: Lippincott-Raven; Ch. 41, 2001. pp. 1305-1340.
[cited by applicant]
Lamb and Parks, “Paramyxoviridae: The viruses and their replication,” B. N. Fields DMK, and P. M. Howley, editor. Fields Virology., 5th ed. Philadelphia: Lippincott-Raven; Ch. 41, 2007. pp. 1449-1496.
[cited by applicant]
Leber et al., “MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism,” Mol. Ther., 19(6): 1097-106, Jun. 2011.
[cited by applicant]
Lee et al., “Activation of innate immunity is required for efficient nuclear reprogramming,” Cell, 151(3):547-58, Oct. 2012.
[cited by applicant]
Lee et al., “Preclinical derivation and imaging of autologously transplanted canine induced pluripotent stem cells,” J. Biol. Chem., 286(37):32697-704, Sep. 2011.
[cited by applicant]
Li et al., “A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression,” Journal of Virology, 74(14):6564-9, Jul. 2000.
[cited by applicant]
Lister et al., “Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells,” Nature., 471(7336): 68-73, Mar. 2011.
[cited by applicant]
Maehr et al., “Generation of pluripotent stem cells from patients with type 1 diabetes,” Proc. Natl. Acad. Sci. USA, 106(37): 15768-15773, Sep. 2009.
[cited by applicant]
Maisner et al., “Recombinant measles virus requiring an exogenous protease for activation of infectivity,” The Journal of general virology, 81(2):441-449, Feb. 2000.
[cited by applicant]
Mali et al., “Improved Efficiency and Pace of Generating Induced Pluripotent Stem Cells from Human Adult and Fetal Fibroblasts,” Stem Cells, 26:1998-2005, Aug. 2008.
[cited by applicant]
Martin, “Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells,” Proc. Natl. Acad. Sci. USA, 78(12):7634-7638, Dec. 1981.
[cited by applicant]
Martinez-Fernandez et al., “c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells,” J Cardiovasc Transl Res., 3(1):13-23, Feb. 2010.
[cited by applicant]
Martinez-Fernandez et al., “iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism,” Circ Res., 105(7):648-656, Sep. 2009.
[cited by applicant]
McAllister et al., “Mechanisms of protein kinase PKR-mediated amplification of beta interferon induction by C protein-deficient measles virus,” J. Virol., 84(1):380-6, Jan. 2010.
[cited by applicant]
Nagano and Fraser, “No-nonsense functions for long noncoding RNAs,” Cell, 145(2):178-181, Apr. 2011.
[cited by applicant]
Nagy et al., “Embryonic stem cells alone are able to support fetal development in the mouse,” Development, 110(3):815-821, Nov. 1990.
[cited by applicant]
Nakagawa et al., “Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts,” Nat Biotechnol., 26(1):101-106, Jan. 2008.
[cited by applicant]
Nakamura et al., “Rescue and propagation of fully retargeted oncolytic measles viruses,” Nat. Biotechnol., 23(2):209-14, Feb. 2005.
[cited by applicant]
Narazaki et al., “Directed and Systematic Differentiation of Cardiovascular Cells From Mouse Induced Pluripotent Stem Cells,” Circulation, 118:498-506, 2008.
[cited by applicant]
Negri et al., “Successful immunization with a single injection of non-integrating lentiviral vector,” Mol. Ther., 15(9):1716-1723, Sep. 2007.
[cited by applicant]
Nelson et al., “Induced pluripotent reprogramming from promiscuous human stemness-related factors,” Clin. Transl. Sci., 2(2):118-126, Apr. 2009.
[cited by applicant]
Nelson et al., “CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells,” Stem Cells, 26(6):1464-1474, Jun. 2008.
[cited by applicant]
Nelson et al., “KCNJ11 knockout morula re-engineered by stem cell diploid aggregation,” Phil. Trans. R. Soc. B., 364(1514):269-276, Jan. 2009.
[cited by applicant]
Nelson et al., “Lineage specification of Flk-1+ progenitors is associated with divergent Sox7 expression in cardiopoiesis,” Differentiation, 77(3):248-255, Mar. 2009.
[cited by applicant]
Nelson et al., “Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells,” Circulation, 120(5):408-416, Aug. 2009.
[cited by applicant]
Nishimura et al., “Development of defective and persistent Sendai virus vector a unique gene delivery/expression system ideal for cell reprogramming,” Bio. Chem. J., 286(6):4760-71, Feb. 2011.
[cited by applicant]
Noser et al., “Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells,” J. Virol., 80(15):7769-7774, Aug. 2006.
[cited by applicant]
Noser et al., “The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells,” Mol. Ther., 15(8):1531-1536, Aug. 2007.
[cited by applicant]
Ohmine et al., “Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency,” Aging (Albany NY), 4(1):60-73, Jan. 2012.
[cited by applicant]
Ohmine et al., “Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells,” Stem Cell Res Ther., 2(6):46, doi: 10.1186/scrt87, 12 pages, Nov. 2011.
[cited by applicant]
Ohmine et al., “Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency,” Aging, 4(1):60-73, Jan. 2012.
[cited by applicant]
Ohmine et al.,“Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells,” Stem Cell Res. Ther., 2(6):46, Dec. 2011.
[cited by applicant]
Okita “Generation of mouse induced pluripotent stem cells without viral vectors,” Science, 322(5903):949-953, Epub Oct. 2008.
[cited by applicant]
Okita et al., “Generation of germline-competent induced pluripotent stem cells,” Nature, 448(7151):313-7, Jul. 2007.
[cited by applicant]
Okita et al., “Generation of mouse induced pluripotent stem cells without viral vectors,” Science, 322(5903):949-53, Nov. 2008.
[cited by applicant]
Okita et al., “Generation of germline-competent induced pluripotent stem cells,” Nature, 448: 313-317, Jul. 19, 2007.
[cited by applicant]
Palmowski et al., “Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response,” J. Immunol., 172(3):1582-1587, Feb. 2004.
[cited by applicant]
Papapetrou et al., “Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation,” Proceedings of the National Academy of Sciences of the Unit…
[cited by applicant]
Paraskevakou et al., “Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas,” Mol. Ther., 15(4):677-86, Apr. 2007.
[cited by applicant]
Parks and Alexander-Miller, “Paramyxovirus activation and inhibition of innate immune responses,” Journal of molecular biology, 425(24):4872-92, Dec. 2013.
[cited by applicant]
Paterson, “Arrhythmia: 100 years on from George Ralph Mines,” J Physiol 591(17):4065-4066, Sep. 1, 2013, 2 pages.
[cited by applicant]
Perez-Terzic et al., “Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport machinery,” Nat. Clin. Pract. Cardiovasc. Med., 4 Suppl 1, S68-76, Feb. 2007.
[cited by applicant]
Perez-Terzic et al., “Structural adaptation of the nuclear pore complex in stem cell-derived cardiomyocytes,” Circ. Res., 92(4):444-452, Mar. 2003.
[cited by applicant]
Philippe et al., “Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo,” Proc Natl Acad Sci U S A., 103(47):17684-17689, Epub Nov. 9, 2006.
[cited by applicant]
Philpott et al., “A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19,” Proc. Natl. Acad. Sci. USA, 99(19):12381-12385, Sep. 2002.
[cited by applicant]
Philpott et al., “Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis,” J. Virol., 76(11):5411-5421, Jun. 2002.
[cited by applicant]
Pless et al., “Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues,” The Journal of infectious diseases, 187(Suppl 1):S291-8, May 2003.
[cited by applicant]
Qi and Pei, “The magic of four: induction of pluripotent stem cells from somatic cells by Oct4, Sox2, Myc and Klf4,” Cell Research, 17(7):578-580, Jul. 2007.
[cited by applicant]
Radecke and Billeter, “The nonstructural C protein is not essential for multiplication of Edmonston B strain measles virus in cultured cells,” Virology, 217(1):418-21, Mar. 1996.
[cited by applicant]
Radecke et al., “Rescue of measles viruses from cloned DNA,” EMBO J., 14(23):5773-84, Dec. 1995.
[cited by applicant]
Rajasingh et al., “Cell-free embryonic stem cell extract-mediated derivation of multipotent stem cells from NIH3T3 fibroblasts for functional and anatomical ischemic tissue repair,” Circ Res., 102(11):e107-117, Jun. 200…
[cited by applicant]
Ramiya et al., “Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells,” Nat. Med., 6(3):278-282, Mar. 2000.
[cited by applicant]
Razak et al., “Profiling of microRNA in human and mouse ES and iPS cells reveals overlapping but distinct microRNA expression patterns,” PLoS One, 8(9):e73532, Sep. 2013.
[cited by applicant]
Relander et al., “Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells,” Mol. Ther., 11(3):452-459, Mar. 2005.
[cited by applicant]
Russell et al., “Remission of disseminated cancer after systemic oncolytic virotherapy,” Mayo Clin. Proc., 89(7): 926-33, Jul. 2014.
[cited by applicant]
Saenz et al., “Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants,” J. Virol., 78(6):2906-2920, Mar. 2004.
[cited by applicant]
Sakuma et al., “Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein, ” Hum. Gene. Ther., 21(12):1665-1673, Sep. 2010.
[cited by applicant]
Sakuma et al., “Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G,” Gene Ther., 14(2):185-189, Jan. 2007.
[cited by applicant]
Schenke-Layland et al., “Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages,” Stem Cells, 26(6):1537-1546, Jun. 2008.
[cited by applicant]
Shimada et al., “Generation of canine induced pluripotent stem cells by retroviral transduction and chemical inhibitors,” Mol. Reprod. Dev., 77(1):2, Jan. 2010.
[cited by applicant]
Solter and Knowles, “Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1),” Proc. Natl. Acad. Sci. USA, 75(11):5565-5569, Nov. 1978.
[cited by applicant]
Sommer et al., “Induced pluripotent stem cell generation using a single lentiviral stem cell cassette,” Stem Cells, 27(3):543-9, Mar. 2009.
[cited by applicant]
Sparrer et al., “Measles virus C protein interferes with beta interferon transcription in the nucleus,” Journal of Virology, 86(2):796-805, Jan. 2012.
[cited by applicant]
Spielhofer et al., “Chimeric measles viruses with a foreign envelope,” Journal of Virology, 72(3):2150-9, Mar. 1998.
[cited by applicant]
Stadler et al., “Characterization of microRNAs involved in embryonic stem cell states,” Stem Cells Dev., 19(7):935-50, Jul. 2010.
[cited by applicant]
Stadtfeld et al., “Induced pluripotent stem cells generated without viral integration,” Science, 322(5903):945-9, Nov. 2008.
[cited by applicant]
Stadtfeld, “Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse,” Cell Stem Cell., 2(3):230-240, Epub Feb. 14, 2008.
[cited by applicant]
Stewart, “Aggregation between teratocarcinoma cells and preimplantation mouse embryos,” J. Embryol. Exp. Morphol., 58:289-302, Aug. 1980.
[cited by applicant]
Strang et al., “Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells,” Gene Ther., 11(7):591-598, Apr. 2004.
[cited by applicant]
Strang et al., “Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells,” J. Virol., 79(3): 1765-1771, Feb. 2005.
[cited by applicant]
Strebel et al., “A world without measles,” The Journal of infectious diseases, 204(Suppl 1):S1-3, Jul. 2011.
[cited by applicant]
Strebel et al., “Global measles elimination efforts: the significance of measles elimination in the United States,” The Journal of infectious diseases, 189(Suppl 1):S251-7, May 2004.
[cited by applicant]
Tahara et al., “Altered interaction of the matrix protein with the cytoplasmic tail of hemagglutinin modulates measles virus growth by affecting virus assembly and cell-cell fusion,” J. Virol., 81(13):6827-36, Jul. 2007.
[cited by applicant]
Takahashi and Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, 126(4):663-676, Epub Aug. 2006.
[cited by applicant]
Takahashi et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, 131(5):861-72, Nov. 2007.
[cited by applicant]
Takaki et al., “Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-β-inducing potential,” Mol. Immunol., 48(4):497-504, Jan. 2011.
[cited by applicant]
Takeda et al., “Generation of measles virus with a segmented RNA genome,” J. Virol., 80(9):4242-8, May 2006.
[cited by applicant]
Takeda et al., “Recovery of pathogenic measles virus from cloned cDNA,” Journal of Virology, 74(14):6643-7, Jul. 2000.
[cited by applicant]
Tateishi et al., “Generation of insulin-secreting islet-like clusters from human skin fibroblasts,” Journal of Biological Chemistry, 283(4):31600-31607, Nov. 2008.
[cited by applicant]
Tateishi et al., “Stemming heart failure with cardiac- or reprogrammed-stem cells,” J Cell Mol Med., 12(6A):2217-2232, Dec. 2008.
[cited by applicant]
Thatava et al., “Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny,” Gene therapy, 18(3):283-293, Mar. 2011.
[cited by applicant]
Thatava et al., “Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation,” Stem Cell Res. Ther., 2(6):48, Dec. 2011.
[cited by applicant]
Thatava et al., “Differentiation of Diabetic Patient-Specific iPS Cells into Insulin-Secreting Cells,” Molecular Therapy, vol. 19, p. S121, abstract 311, May 2011.
[cited by applicant]
Thatava et al., “Generation of glucose-responsive insulin-secreting cells from Type 1 Diabetes-specific induced pluripotent stem cells,” 2011 Meeting on Stem Cell Engineering & Cell-based Therapies: Apr. 7-10, 2011, Col…
[cited by applicant]
Thatava et al., “Generation of insulin-secreting cells from human induced pluripotent stem cells,” American Society of Gene and Cell Therapy 13th Annual Meeting, Washington, DC USA, May 19-22, 2010, 18 slides.
[cited by applicant]
Thatava et al., “Generation of insulin-secreting cells from human induced pluripotent stem cells,” Molecular Therapy, vol. 18, p. S246, abstract 633, May 2010.
[cited by applicant]
Thatava et al., “Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny,” Gene Therapy, 18:283-293, Mar. 2011.
[cited by applicant]
Thatava et al., “Pancreatic differentiation of diabetic patient-specific iPS cells,” American Society of Gene and Cell Therapy, 14th Annual Meeting, Seattle, WA, USA, May 18-21, 2011, 20 pages.
[cited by applicant]
Thomson et al., “Embryonic stem cell lines derived from human blastocysts,” Science, 282(5391):1145-1147, Nov. 1998.
[cited by applicant]
Tiemann et al., “Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells,” Cytometry Part A, 79(6):426-435, Jun. 2011.
[cited by applicant]
Ungerechts et al., “Lymphoma chemovirotherapy: CD20-targeted and convertase- armed measles virus can synergize with fludarabine,” Cancer Res., 67(22):10939-47, Nov. 2007.
[cited by applicant]
von Messling et al., “The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity,” J. Virol., 75(14):6418-27, Jul. 2001.
[cited by applicant]
Vulliemoz and Roux, ““Rule of six”: how does the Sendai virus RNA polymerase keep count?” Journal of Virology, 75(10):4506-4518, May 2001.
[cited by applicant]
Wernig et al., “Neurons derived from reprogrammed fibroblasts functionall integrate into the fetal brain and improve symptoms of rats with Parkinson's disease,” PNAS., 105(15):5856-5861, Apr. 15, 2008.
[cited by applicant]
Wernig et al., “c-Myc is dispensable for direct reprogramming of mouse fibroblasts,” Cell Stem Cell, 2(1):10-12, Jan. 2008.
[cited by applicant]
Wolf and Goff, “TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells,” Cell, 131(1):46-57, Oct. 2007.
[cited by applicant]
Woltjen et al., “piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells,” Nature, 458(7239):766, Apr. 2009.
[cited by applicant]
Wood et al., “Non-injection methods for the production of embryonic stem cell-embryo chimaeras,” Nature, 365(6441):87-89, Sep. 1993.
[cited by applicant]
Xu et al., “Phenotypic correction of murine hemophilia A using an iPS cell-based therapy,” PNAS., 106(3):808-813, Jan. 2009.
[cited by applicant]
Yaiw et al., “CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy,” Gene. Ther., 18(3):313-7, Mar. 2011.
[cited by applicant]
Yamada et al., “Embryonic stem cell therapy of heart failure in genetic cardiomyopathy,” Stem Cells, 26:2644-2653, Oct. 2008.
[cited by applicant]
Yamada et al., “Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction,” J Physiol., 591(17)4335-4349, Epub, Apr. 8, 2013.
[cited by applicant]
Yamanaka, “Pluripotency and nuclear reprogramming,” Philos Trans R Soc Lond B Biol Sci., 363(1500):2079-2087, Jun. 2008.
[cited by applicant]
Yáñez-Muñoz et al., “Effective gene therapy with nonintegrating lentiviral vectors,” Nat Med., 12(3):348-353, Mar. 2006.
[cited by applicant]
Yonemitsu et al., “DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial,” Mol. Ther., 21(3):707-14, Mar. 2013.
[cited by applicant]
Yu et al., “Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies,” Stem Cell Res., 9(3):196-207, Epub Jun. 28, 2012.
[cited by applicant]
Yu et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science, 318(5858):1917-1920, print Dec. 2007, Epub Nov. 2007.
[cited by applicant]
Yu et al., “Transient gene expression mediated by integrase-defective retroviral vectors,” Biochem Biophys Res Commun., 368(4):942-947, Epub Feb. 13, 2008.
[cited by applicant]
Yuasa and Fukuda, “Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era,” Expert Rev Cardiovasc Ther., 6(6):803-810, Jul. 2008.
[cited by applicant]
Zawalich and Zawalich, “Effects of glucose, exogenous insulin, and carbachol on C-peptide and insulin secretion from isolated perifused rat islets,” J Biol Chem., 277(29):26233-26237, Epub May 13, 2002.
[cited by applicant]
Zhou et al., “Generation of induced pluripotent stem cells using recombinant proteins,” Cell Stem Cell, 4(5):381-4, May 2009.
[cited by applicant]
Zufferey et al., “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo,” Nat. Biotechnol., 15(9):871-875, Sep. 1997.
[cited by applicant]
Cataliotti et al., “Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats,” Circulation, Mar. 14, 2011, 123(12):1297-130…
[cited by applicant]
Cattaneo et al., “Altered transcription of a defective measles virus genome derived from a diseased human brain,” EMBO Journal, Mar. 1987, 6(3):681-688.
[cited by applicant]
Chan et al., “Induction of a human pluripotent state with distinct regulatory circuitry that resembles preimplantation epiblast,” Cell Stem Cell, Dec. 5, 2013, 13(6):663-675.
[cited by applicant]
Devaux et al., “Measles Vectors as a New Platform for the Production of Induced- pluripotent stem cells (iPSCs),” Abstract, Presented at Proceedings of IMV 2013, Minneapolis, MN, USA, May 13, 2013, 1 page.
[cited by applicant]
Devaux et al., “Measles Vectors as a New Platform for the Production of Induced- pluripotent stem cells (iPSCs),” Abstract, Presented at Proceedings of Measles Virus Minisymposia, Annecy, France, Sep. 9-10, 2013, 1 page.
[cited by applicant]
Driscoll et al., “Measles virus, a new tool for nuclear reprogramming: a proof of principle,” Abstract, Presented at Proceedings of IMV 2014, Minneapolis MN, USA, May 12, 2014, 1 page.
[cited by applicant]
Driscoll et al., “Nuclear reprogramming with a non-integrating human RNA virus,” Abstract, Presented at Proceedings of IMV 2015, Minneapolis, MN, USA, May 11, 2015, 1 page.
[cited by applicant]
El-Khatib et al., “Tumor-free transplantation of patient-derived induced pluripotent stem cells progeny for customized islet regeneration,” Stem Cells Transl. Medicine, May 2016, 5(5):694-702.
[cited by applicant]
Folmes et al., “Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming,” Cell Metabolism, Aug. 3, 2011, 14(2):264-271.
[cited by applicant]
Gafni et al., “Derivation of novel human ground state naive pluripotent stem cells,” Nature, Dec. 12, 2013, 504(7479):282-286.
[cited by applicant]
Garber, “Riken suspends first clinical trial involving induced pluripotent stem cells,” Nat. Biotechnology, Sep. 2014, 33(9):890-891.
[cited by applicant]
Hu et al., “Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells,” Regen. Medicine, Dec. 18, 2015, 11(1):105-132.
[cited by applicant]
JapanTimes.co.jp [online], “First iPS cell transplant patient makes progress one year on,” Oct. 2, 2015, retrieved on May 10, 2022, retrieved from URL<https://www.japantimes.co.jp/news/2015/10/02/national/science-health…
[cited by applicant]
Kärber, “Contribution to the collective treatment of pharmacological series experiments,” Arch. Exp. Pathol. Pharmakologie, 1931, 162(4):480-483 (with Machine English Translation).
[cited by applicant]
Kimbrel et al., “Current status of pluripotent stem cells: moving the first therapies to the clinic,” Nat. Rev. Drug Discovery, Sep. 22, 2015, 14(10):681-692.
[cited by applicant]
Lin et al., “A chemical platform for improved induction of human iPSCs,” Nat. Methods, Nov. 2009, 6(11):805-808.
[cited by applicant]
Mandai et al., “Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration,” N. Engl. J. Medicine, Mar. 16, 2017, 376(11):1038-1046.
[cited by applicant]
Moszynski, “Measles campaign's “historic victory” for global public health,” BMJ, Jan. 25, 2007, 334:177, 2 pages.
[cited by applicant]
Normile, “iPS cell therapy reported safe,” Science, Mar. 17, 2017, 355(6330):1109-1110.
[cited by applicant]
Pagliuca et al., “Generation of functional human pancreatic β cells in vitro,” Cell, Oct. 9, 2014, 159(2):428-439.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/US2017/054268 dated Apr. 2, 2019, 9 pages.
[cited by applicant]
Pera, “Stem cells: The dark side of induced pluripotency,” Nature, Mar. 3, 2011, 471(7336):46-47.
[cited by applicant]
Rezania et al., “Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells,” Nat. Biotechnology, Sep. 11, 2014, 32:1121-1133.
[cited by applicant]
Sakuma et al., “Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins,” Nat. Medicine, May 2007, 13(5):631-635.
[cited by applicant]
Schlaeger et al., “A comparison of non-integrating reprogramming methods,” Nat. Biotechnology, Dec. 1, 2014, 33(1):58-63.
[cited by applicant]
Shi et al., “Induced pluripotent stem cell technology: a decade of progress,” Nat. Rev. Drug Discovery, Dec. 16, 2016, 16:115-130.
[cited by applicant]
Shimojima et al., “Use of CD134 as a primary receptor for the feline immunodeficiency virus,” Science, Feb. 20, 2004, 303(5661):1192-1195.
[cited by applicant]
Thatava et al., “Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells,” Mol. Therapy, Nov. 27, 2012, 21(1):228-239.
[cited by applicant]
Theunissen et al., “Systematic identification of culture conditions for induction and maintenance of naive human pluripotency,” Cell Stem Cell, Jul. 24, 2014, 15(4):471-487.
[cited by applicant]
Toth et al., “Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus,” J. Virology, Nov. 12, 2008, 83(2):961-968.
[cited by applicant]
Trounson et al., “Pluripotent stem cells progressing to the clinic,” Nat. Rev. Mol. Cell Biology, Feb. 23, 2016, 17(3):194-200.
[cited by applicant]
Valamehr et al., “Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells,” Stem Cell Report, Mar. 6, 2014, 2(3):366-381.
[cited by applicant]
Ware et al., “Derivation of naïve human embryonic stem cells,” Proc. Natl. Acad. Sci. USA, Mar. 12, 2014, 111(12):4484-4489.
[cited by applicant]
Rallabandi et al., “miRNA-mediated control of exogenous OCT4 during mesenchymal-epithelial transition increases measles vector reprogramming efficiency,” Mol. Ther. Methods Clin. Development, 24:48-61, Nov. 29, 2021.
[cited by applicant]
Rallabandi et al., “Supplemental Information: miRNA-mediated control of exogenous OCT4 during mesenchymal-epithelial transition increases measles vector reprogramming efficiency,” Mol. Ther. Methods Clin. Development, N…
[cited by applicant]
Wang et al., “Measles vector as a multiple genes delivery platform facilitating iPSC reprogramming,” Gene Therapy, 26(5):151-164, Feb. 4, 2019.
[cited by applicant]
Wang et al., “Supplementary Information: Measles vector as a multiple genes delivery platform facilitating iPSC reprogramming,” Gene Therapy, Feb. 4, 2019, 6 pages.
[cited by applicant]
Bernal, “RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications,” J. Cardiovasc. Transl. Res., Dec. 2013, 6(6):956-968.
[cited by applicant]
Hu, “Vectorology and factor delivery in induced pluripotent stern cell reprogramming,” Stem Cells Dev., Jun. 2014, 23(12):1301-1315.
[cited by applicant]
Yue et al., “Reprogramming of somatic cells induced by fusion of embryonic stem cells using hemagglutinating virus of Japan envelope (HVJ-E),” Biochem. Biophys. Res. Commun., Apr. 2010, 394(4):1053-1057.
[cited by applicant]